DNLI
Denali Therapeutics Inc.
Biotechnology · Healthcare · United States
18.94
close · 2026-10-30
value
71
cheaper than peers71
quality
59
stronger fundamentals59
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -5.6% | 86 |
| earnings yield, 3 years ago | -13.7% | 72 |
| earnings yield, 1 year ago | -13.6% | 66 |
| earnings yield, latest year | -15.7% | 61 |
| cash flow yield, 3 years ago | -8.7% | 57 |
| cash flow yield, 1 year ago | -12.0% | 57 |
| cash flow yield, latest year | -13.9% | 56 |
| cash flow yield, 2 years ago | -12.3% | 55 |
| price to book | 3.62× | 38 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -49.6% | 65 |
| debt to equity | 4.3% | 51 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | -$190.3M |
| employees | 507 |
| first trade | 2017-12-08 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.97 | -2.57 | -1.06 | -2.60 |
| free cash flow | -$422.1M | -$363.6M | -$370.9M | -$262.5M |
| net income | -$512.5M | -$422.8M | -$145.2M | -$326.0M |
| revenue | $0 | $0 | $330.5M | $108.5M |
| unusual items | $0 | $14.5M | $0 | $0 |